GUCY2c is a tumor target expressed in >90% of colorectal cancer (CRC). It is also expressed on the apical side of intestinal epithelial tight junctions, where it regulates intestinal fluidity. PF-07062119, a GUCY2c-CD3 bispecific antibody that recruits T cells to GUCY2c expressing ...
本发明提供了一种抗GUCY2C/CD3双特异性抗体,包含与靶分子A结合的结构域A和与靶分子B结合的结构域B;所述靶分子A和靶分子B选自GUCY2C和CD3;所述结构域A和结构域B选自抗GUCY2C的抗体或其抗原结合片段和抗CD3的抗体或其抗原结合片段。本发明的抗GUCY2C/CD3双特异性抗体具有优良的靶向性、特异性、以及显著的...
In this study, we demonstrated the initial steps to qualify the ability of the CD8 Mb PET tracer89Zr-Df-IAB22M2C to quantify the recruitment of human CD8+ T cells to tumors following treatment with the GUCY2C-CD3 BsAb PF-07062119 with high sensitivity and robustness. The PET tracer was ...
Additionally, to address immune evasion mechanisms, combinations of the GUCY2C-CD3 bispecific are explored with immune checkpoint blockade therapy, as well as with chemotherapeutic and anti-angiogenic agents that could enhance immune infiltration into tumors. Our preclinical in vivo data demonstrate that...